Efficacy and Safety of Butorphanol Tartrate Injection for the Patients With Mechanical Ventilation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-31

Study Completion Date

2023-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare the incidence of hospital-acquired infections between butorphanol and fentanyl.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Fentanyl vs. Low-Dose Ketamine for the Relief of Moderate to Severe Pain in Aeromedical Patients

NCT01169025

Trauma Pain

WITHDRAWN NA

Efficacy and Safety Study of Fentanyl Transdermal (Fentanest®)

NCT00959400

Pain Palliative Care

WITHDRAWN PHASE3

Determination of Analgesic Equipotent Doses of Inhaled Metoxyflurane vs. Intravenous Fentanyl

NCT03894800

Acute Pain Trauma Hypovolemia

COMPLETED PHASE4

Nebulized Fentanyl in Healthy Volunteers

NCT06281951

Analgesia Emergencies

RECRUITING PHASE1

Sublingual Sufentanil vs Intravenous Fentanyl for Acute Pain in the Ambulatory Surgery Center

NCT04177862

Pain Pain, Acute Anesthesia

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Butorphanol can improve inflammation and promote the recovery of pro-inflammatory/anti-inflammatory cytokine balance.However, there is still a lack of relevant clinical studies on butorphanol and fentanyl for the incidence of hospital-acquired infections in ICU mechanically ventilated patients.The objective of this study was to evaluate the analgesic efficacy,safety and the incidence of nosocomial infection of butorphanol in mechanical ventilation patients between butorphanol and fentanyl.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Analgesia Hospital-acquired Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Butorphanol tartrate

Butorphanol tartrate on the patients with mechanical ventilation

Group Type EXPERIMENTAL

Butorphanol Tartrate Injection

Intervention Type DRUG

Patients of this group will receive Butorphanol Tartrate Injection

fentanyl

fentanyl on the patients with mechanical ventilation

Group Type ACTIVE_COMPARATOR

Fentanyl

Intervention Type DRUG

Patients of this group will receive Fentanyl

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Butorphanol Tartrate Injection

Patients of this group will receive Butorphanol Tartrate Injection

Intervention Type DRUG

Fentanyl

Patients of this group will receive Fentanyl

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

the drug of butorphanol tartrate the drug of fentanyl

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* need mechanical ventilation for more than 48 hours
* more than 18 years old
* without hospital-acquired infection before admission to ICU
* volunteer to participate in this study

Exclusion Criteria

* allergic or contraindicated to the drug
* severe cardiac insufficiency, conduction block and bradycardia
* recent use of analgesic, sedative and antidepressant drugs
* psychiatric or neurological diseases or neurosurgery-related diseases
* history of steroid cortisol and immunosuppressants
* severe liver dysfunction or renal dysfunction
* pregnancy
* refuse to enrollment

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No